GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (FRA:LDBB) » Definitions » Price-to-Free-Cash-Flow

H. Lundbeck AS (FRA:LDBB) Price-to-Free-Cash-Flow : 7.76 (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Price-to-Free-Cash-Flow?

As of today (2024-06-05), H. Lundbeck AS's share price is €4.33. H. Lundbeck AS's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.56. Hence, H. Lundbeck AS's Price-to-Free-Cash-Flow Ratio for today is 7.76.

The historical rank and industry rank for H. Lundbeck AS's Price-to-Free-Cash-Flow or its related term are showing as below:

FRA:LDBB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.7   Med: 9.2   Max: 24.91
Current: 8.08

During the past 13 years, H. Lundbeck AS's highest Price-to-Free-Cash-Flow Ratio was 24.91. The lowest was 6.70. And the median was 9.20.

FRA:LDBB's Price-to-Free-Cash-Flow is ranked better than
86.23% of 523 companies
in the Drug Manufacturers industry
Industry Median: 22.83 vs FRA:LDBB: 8.08

H. Lundbeck AS's Free Cash Flow per Share for the three months ended in Mar. 2024 was €0.12. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €0.56.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of H. Lundbeck AS was 25.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -40.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -37.50% per year.

During the past 13 years, H. Lundbeck AS's highest 3-Year average Free Cash Flow per Share Growth Rate was 277.90% per year. The lowest was -68.80% per year. And the median was -2.50% per year.


H. Lundbeck AS Price-to-Free-Cash-Flow Historical Data

The historical data trend for H. Lundbeck AS's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Price-to-Free-Cash-Flow Chart

H. Lundbeck AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 8.79 7.96

H. Lundbeck AS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.79 8.58 9.42 7.96 6.87

Competitive Comparison of H. Lundbeck AS's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Price-to-Free-Cash-Flow falls into.



H. Lundbeck AS Price-to-Free-Cash-Flow Calculation

H. Lundbeck AS's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=4.33/0.558
=7.76

H. Lundbeck AS's Share Price of today is €4.33.
H. Lundbeck AS's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.56.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

H. Lundbeck AS  (FRA:LDBB) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


H. Lundbeck AS Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


H. Lundbeck AS (FRA:LDBB) Business Description

Address
Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS (FRA:LDBB) Headlines

No Headlines